標(biāo)題: Titlebook: Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions; Manjunath P. Pai,Jennifer J. Kiser,Keith A. Rodvol Book 2018Lat [打印本頁(yè)] 作者: 加冕 時(shí)間: 2025-3-21 18:33
書(shū)目名稱(chēng)Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions影響因子(影響力)
書(shū)目名稱(chēng)Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions被引頻次
書(shū)目名稱(chēng)Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions被引頻次學(xué)科排名
書(shū)目名稱(chēng)Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions年度引用
書(shū)目名稱(chēng)Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions年度引用學(xué)科排名
書(shū)目名稱(chēng)Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions讀者反饋
書(shū)目名稱(chēng)Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions讀者反饋學(xué)科排名
作者: epicardium 時(shí)間: 2025-3-21 20:17 作者: gait-cycle 時(shí)間: 2025-3-22 02:29 作者: 馬具 時(shí)間: 2025-3-22 08:34
Community and Nationhood, Government, Warram-positive microorganism. Over 50 years of clinical experience with the macrolides has also led to the observation of non-antimicrobial properties that are now being exploited in clinical practice. Two forms of hepatic injury have been attributed to these classes, the idiosyncratic form of which h作者: 粗語(yǔ) 時(shí)間: 2025-3-22 10:14 作者: Enzyme 時(shí)間: 2025-3-22 13:24
https://doi.org/10.1007/978-981-16-6526-4 drugs are primarily renally eliminated; therefore, CYP450 interactions are not of concern. Daptomycin, the only agent in the class of lipopeptides, should be closely monitored with other drugs that are likely to cause muscle damage, especially HMG-CoA reductase inhibitors, due to adverse events rel作者: Enzyme 時(shí)間: 2025-3-22 19:07 作者: 表主動(dòng) 時(shí)間: 2025-3-22 23:53 作者: 不理會(huì) 時(shí)間: 2025-3-23 01:53 作者: 雪上輕舟飛過(guò) 時(shí)間: 2025-3-23 06:14 作者: 不愿 時(shí)間: 2025-3-23 11:59
Vision-and-Language Pretraining for VQAhave a low potential for drug interactions but are not devoid of interactions. The treatment of hepatitis C virus has rapidly evolved in recent years. Combinations of agents including inhibitors of the nonstructural (NS) viral protein NS5B polymerase, NS5A, and/or NS3 protease with or without the pu作者: 浮夸 時(shí)間: 2025-3-23 16:13 作者: myelography 時(shí)間: 2025-3-23 19:25
https://doi.org/10.1007/978-981-19-0964-1with a significant number of drugs. Interactions involving amphotericin B are a function of its adverse effects. The azoles primarily inhibit the biotransformation or transport of other medicines, which affects their distribution and elimination. The echinocandins have the lowest propensity to inter作者: 地名詞典 時(shí)間: 2025-3-24 00:12 作者: Redundant 時(shí)間: 2025-3-24 05:13 作者: Interstellar 時(shí)間: 2025-3-24 08:28 作者: frozen-shoulder 時(shí)間: 2025-3-24 14:08 作者: Integrate 時(shí)間: 2025-3-24 16:04 作者: STEER 時(shí)間: 2025-3-24 21:58
Drugs for Tuberculosis, the treatment of tuberculosis and human immunodeficiency virus is discussed. Most drug interactions with antituberculosis drugs are a result of effects on hepatic enzyme metabolism. Interactions with drugs affecting absorption also?are reviewed.作者: 闖入 時(shí)間: 2025-3-25 00:21 作者: MURKY 時(shí)間: 2025-3-25 03:50 作者: MAIZE 時(shí)間: 2025-3-25 07:37 作者: Oafishness 時(shí)間: 2025-3-25 12:27
ntimalarial and antiprotozoal drug classes.New chapters dedi.The 4.th. edition of .Drug Interactions in Infectious Diseases .is being split into two separate volumes – “Mechanisms and Models of Drug Interactions” and “Antimicrobial Drug Interactions”. ..This volume, “Antimicrobial Drug Interactions,作者: Coma704 時(shí)間: 2025-3-25 17:06
Anshuman Behera,Areeba Ahsanat Moazzam the treatment of tuberculosis and human immunodeficiency virus is discussed. Most drug interactions with antituberculosis drugs are a result of effects on hepatic enzyme metabolism. Interactions with drugs affecting absorption also?are reviewed.作者: 上下倒置 時(shí)間: 2025-3-25 21:14
Anshuman Behera,Areeba Ahsanat Moazzamass is also being investigated as part of nucleos(t)ide analog-sparing regimens and as long-acting injectables for HIV treatment and prevention. This chapter reviews the pharmacology and drug interaction potential of PIs and INIs used in the treatment of HIV with summary tables to guide patient management.作者: Chronic 時(shí)間: 2025-3-26 03:18 作者: deficiency 時(shí)間: 2025-3-26 08:10
Vision-and-Language Pretraining for VQArmacokinetic properties and drug interaction potential of agents used in the treatment of hepatitis B and C viruses, as well as pharmacologic considerations on the use of these therapies in patients with renal or hepatic impairment.作者: 母豬 時(shí)間: 2025-3-26 10:42 作者: 鴿子 時(shí)間: 2025-3-26 14:08
Drug Interactions in HIV: Nucleoside, Nucleotide, and Nonnucleoside Reverse Transcriptase Inhibitor CCR5 antagonist, maraviroc, may also be victims of drug-drug interactions related to cytochrome P450 metabolism. This chapter emphasizes the clinical significance and management of common drug interactions associated with these antiretroviral drug classes.作者: 一起 時(shí)間: 2025-3-26 17:33
Hepatitis B and Hepatitis C Antiviral Agents,rmacokinetic properties and drug interaction potential of agents used in the treatment of hepatitis B and C viruses, as well as pharmacologic considerations on the use of these therapies in patients with renal or hepatic impairment.作者: Immunotherapy 時(shí)間: 2025-3-26 21:53
Antifungal Agents,act with other medicines. The clinical relevance of antifungal-drug interactions varies substantially. This chapter reviews the pharmacology, pharmacokinetic properties of antifungal agents, and their clinically relevant drug interactions.作者: motor-unit 時(shí)間: 2025-3-27 03:16 作者: 得罪人 時(shí)間: 2025-3-27 07:30
Macrolides, Azalides, and Ketolides,ram-positive microorganism. Over 50 years of clinical experience with the macrolides has also led to the observation of non-antimicrobial properties that are now being exploited in clinical practice. Two forms of hepatic injury have been attributed to these classes, the idiosyncratic form of which h作者: Outspoken 時(shí)間: 2025-3-27 09:44 作者: anthesis 時(shí)間: 2025-3-27 13:43
Glycopeptides, Lipopeptides, and Lipoglycopeptides, drugs are primarily renally eliminated; therefore, CYP450 interactions are not of concern. Daptomycin, the only agent in the class of lipopeptides, should be closely monitored with other drugs that are likely to cause muscle damage, especially HMG-CoA reductase inhibitors, due to adverse events rel作者: 終端 時(shí)間: 2025-3-27 18:05
Miscellaneous Antibiotics, which are older agents that are less frequently prescribed, so many clinicians may not be familiar with their interactions with other medications. It also reviews the interactions with tigecycline and quinupristin-dalfopristin, two agents that are the only available agents from classes of antibioti作者: 威脅你 時(shí)間: 2025-3-28 01:42 作者: 獸皮 時(shí)間: 2025-3-28 05:12 作者: BAIT 時(shí)間: 2025-3-28 08:41 作者: Harass 時(shí)間: 2025-3-28 12:06 作者: Scleroderma 時(shí)間: 2025-3-28 17:24
Drug Interactions of Non-HIV Antiviral Agents,higher risk for severe viral infections such as those caused by cytomegalovirus (CMV), adenovirus, and disseminated herpes simplex virus (HSV). Infection with hepatitis C virus (HCV) is common, and many new antiviral regimens have come into use for management of infected patients. Influenza continue作者: 許可 時(shí)間: 2025-3-28 19:44 作者: STEER 時(shí)間: 2025-3-29 02:15
Drug-Drug Interactions of Antimalarial Drugs,of Africa, Asia, and the Americas. Combination chemotherapy is recommended for treatment of acute uncomplicated malaria as a result of widespread drug resistance. Tuberculosis (Tb) is also widespread and combination therapy is its standard of care. Treatment of malaria in an individual on antituberc作者: Processes 時(shí)間: 2025-3-29 04:09
Antiprotozoal and Anthelmintic Agents,therapy with the wish to minimize emergence of drug resistance. Throughout the past few decades, the clinical pharmacokinetics and metabolism of many antiparasitic agents have been elucidated, particularly the role of drug-metabolizing enzymes, notably cytochromes P450, and drug transporter proteins作者: 腐蝕 時(shí)間: 2025-3-29 08:23
Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions作者: PSA-velocity 時(shí)間: 2025-3-29 13:18
Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions978-3-319-72416-4作者: 昏迷狀態(tài) 時(shí)間: 2025-3-29 16:40
Book 2018Latest edition interactions in hepatitis B virus (HBV) and hepatitis C virus (HCV)-relatedinfections is included. ?Two new chapters are dedicated to the management of human immunodeficiency virus (HIV) drug-drug interactions given the breadth of antiretroviral class-specific effects. This comprehensive review of 作者: FLINT 時(shí)間: 2025-3-29 19:42
Beta-Lactam Antibiotics,umentation is needed and/or potential harm to the patient is less. Minor interactions are either poorly documented, present minimal potential harm to the patient, or occur with a low incidence..The drug interactions of most concern with the beta-lactam antibiotics are those with oral contraceptive p作者: obtuse 時(shí)間: 2025-3-30 00:53 作者: arthroscopy 時(shí)間: 2025-3-30 04:19
Quinolones,ee less widely available FQs (antofloxacin, nemonoxacin, and prulifloxacin) act as moderate cytochrome P450 enzyme inhibitors and may increase serum concentrations of theophylline and caffeine. Warfarin pharmacodynamics are variably affected by the FQs. The pharmacodynamic interactions between NSAID
